3 Promising Penny Stocks With Market Caps Over $40M To Watch

In the last week, the market has been flat, but over the past 12 months, it has risen by 14%, with earnings expected to grow by 17% per annum in the coming years. For investors interested in smaller or newer companies, penny stocks—despite their somewhat outdated label—remain an intriguing area of exploration. These stocks can offer a blend of value and growth potential when backed by strong financials, making them worthy candidates for those seeking hidden opportunities in today's market landscape.

Let's review some notable picks from our screened stocks.

Nephros (NEPH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nephros, Inc. is a commercial-stage company that develops and sells water filtration solutions for medical and commercial applications in the United States, with a market cap of $48.54 million.

Operations: The company's revenue is primarily derived from its Water Filtration segment, excluding Pathogen Detection, which generated $20.72 million.

Market Cap: $48.54M

Nephros, Inc. has shown promising financial performance with a recent revenue increase to US$6.02 million in Q2 2026, up from US$4.42 million the previous year, and net income rising to US$1.2 million. The company is debt-free, enhancing its financial stability and flexibility for strategic growth initiatives like acquisitions or investments as mentioned by CFO Judy F. Krandel. Despite having a low return on equity of 14.5%, Nephros has achieved significant earnings growth over the past five years at 57.2% annually, outperforming its industry peers and maintaining high-quality earnings without shareholder dilution recently.

• Unlock comprehensive insights into our analysis of Nephros stock in this financial health report.
• Gain insights into Nephros' outlook and expected performance with our report on the company's earnings estimates.

Siebert Financial (SIEB)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Siebert Financial Corp. operates in the United States, offering brokerage and financial advisory services, with a market capitalization of $110.97 million.

Operations: The company generates revenue primarily from Financial Services, contributing $102.62 million, and Media, Sports and Entertainment activities, adding $1.72 million.

Market Cap: $110.97M

Siebert Financial Corp. has been active in strategic partnerships, notably with Unusual Whales and FusionIQ, to enhance its ETF offerings and digital wealth capabilities. Despite a market capitalization of US$110.97 million and assets under management of around US$19 billion, the company faces challenges such as recent index exclusions from multiple Russell indices and ongoing unprofitability with a net loss of US$2.3 million for the first half of 2026. However, Siebert's short-term assets exceed both its short- and long-term liabilities, providing some financial stability amidst high debt levels relative to equity.

• Dive into the specifics of Siebert Financial here with our thorough balance sheet health report.
• Explore historical data to track Siebert Financial's performance over time in our past results report.

Elite Pharmaceuticals (ELTP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and selling oral controlled-release and generic pharmaceuticals, with a market cap of $283.29 million.

Operations: The company's revenue is primarily derived from its Abbreviated New Drug Applications (ANDA) segment, which generated $141.01 million.

Market Cap: $283.29M

Elite Pharmaceuticals has demonstrated a strong financial position with its recent profitability, reporting a net income of US$5.91 million for Q1 2026, reversing a loss from the previous year. The company benefits from seasoned management and board teams, which contribute to its strategic execution in launching generic drugs like Ropinirole Extended-Release Tablets. Elite's robust cash flow covers debt well, and it maintains more cash than total debt, indicating prudent financial management. Despite a decrease in sales to US$32.36 million this quarter compared to last year, Elite's return on equity remains outstanding at 54.1%.

• Jump into the full analysis health report here for a deeper understanding of Elite Pharmaceuticals.
• Examine Elite Pharmaceuticals' past performance report to understand how it has performed in prior years.

Turning Ideas Into Actions

• Click this link to deep-dive into the 318 companies within our US Penny Stocks screener.
• Curious About Other Options? AI is about to change healthcare. These 129 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com